



**Format for disclosures under Regulation 29(2) of SEBI
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	BLISS GVS PHARMA LTD		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	See attached Schedule for breakdown of funds under the management of FMR LLC and its direct and indirect subsidiaries and FIL Limited and its direct and indirect subsidiaries		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Ltd. BSE Ltd		
Details of the acquisition /disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition/disposal under consideration, holding of :			
a) Shares carrying voting rights	5,489,635	5.32%	N/A
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	5,489,635	5.32%	N/A
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	(2,045,474)	-2.00%	N/A
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/ sold			



d) Shares encumbered/ invoked/ released by the acquirer/ seller			
e) Total (a+b+c+/-d)	(2,045,474)	-2.00%	N/A
After the acquisition/sale, holding of:			
a) Shares carrying voting rights	3,444,161	3.32%	N/A
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition/ sale.			
e) Total (a+b+c+d)	3,444,161	3.32%	N/A
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	08 February 2018 - 14 March 2022		
Equity share capital / total voting capital of the TC before the said acquisition / sale	103,146,667		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	103,677,922		
Total diluted share/voting capital of the TC after the said acquisition/sale	N/A		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 5 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / Authorised Signatory

Charles Guo
Senior Manager of Regulatory Reporting, Asia Pacific

Duly authorized under Powers of Attorney by and on behalf of FMR LLC & FIL Limited

Place: C/O FIL Asia Pte Ltd, Level 21, 88 Queensway, Admiralty, Hong Kong

Date: 16 March 2022



Schedule

	Fund	Shares Held	% of shares and voting rights held
Funds under the management of FMR LLC and its direct and indirect subsidiaries and FIL Limited and its direct and indirect subsidiaries	FID LP STK K6 PRIN ALL SEC SUB	223,698	0.22
	FID LOW PRICE STK PRIN ALL SEC	2,829,755	2.73
	FID LP STK CP PRALSC SB T16852	390,708	0.38
Total		3,444,161	3.32



FIL Investment Management (Hong Kong) Limited
Level 21, Two Pacific Place, 88 Queensway
Admiralty, Hong Kong

Tel: (852) 2629 2800
Fax: (852) 2845 9051

BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
India

Fax: +91 22 2272 1919
Tel: +91 22 2272 1233 / 4, +91 22 6654 5695

16 March 2022

Dear Sir/Madam:

Enclosed please find a copy of regulatory filings for **BLISS GVS PHARMA LTD.**

- Regulatory filing required under regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011

Should you have any questions, please contact us at email apac.regulatory.filings@fil.com or via Fax on +852 2629 9669.

Yours faithfully,

A handwritten signature in black ink that reads 'Charles Gung'.

Regulatory Reporting, Asia Pacific

Encl.